Subsidy Information and Financing Scheme SDLUrsodeoxycholic Acid Capsule 250 mg SDLUrsodeoxycholic Acid Suspension 50 mg/mL SDLUrsodeoxycholic Acid Tablet 500 mg
Drug Guidance for Subsidy 01/09/2020 Ursodeoxycholic acid for treating primary biliary cirrhosis The Ministry of Health’s Drug Advisory Committee has recommended: Ursodeoxycholic acid 250 mg caps... See all × 01/09/2020 Ursodeoxycholic acid for treating primary biliary cirrhosis The Ministry of Health’s Drug Advisory Committee has recommended: Ursodeoxycholic acid 250 mg capsule, 500 mg tablet and 50 mg/ml suspension for treating primary biliary cirrhosis in patients without decompensated hepatic cirrhosis. Subsidy status RUrsodeoxycholic acid 250 mg capsule, 500 mg tablet and 50 mg/ml suspension are recommended for inclusion on the MOH Standard Drug List (SDL). RUrsodeoxycholic acid 50 mg/ml suspension does not have regulatory approval with the Health Sciences Authority (HSA). The responsibility of prescribing an unregistered product to patients lies with the treating clinician. Before treatment is started, it is important to consider the availability of other suitable registered alternatives and inform the patient or their carer that the product is unregistered.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Capsule 250 mg Alexandra Hospital Changi General Hospital KK Women's and Children's Hospital Khoo Teck Puat Hospital National Cancer Centre Ng Teng Fong General Hospital National University Hospital Sengkang General Hospital Singapore General Hospital Tan Tock Seng Hospital Suspension 50 mg/mL KK Women's and Children's Hospital National University Hospital
ORAL Select a brand starting with the letter: G U GRINTEROL HARD CAPSULE 250MG [SIN15883P] URSOFALK CAPSULE 250 MG [SIN05742P] URSOFALK FILM-COATED TABLETS 500MG [SIN14545P]